Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Jun;10(8):657-663.
doi: 10.2217/imt-2017-0190. Epub 2018 Mar 22.

A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer

Elie El Rassy  1 , Ziad Bakouny  1 , Fouad Aoun  2 , Fadi G Haddad  1 , Ghassan Sleilaty  3 , Tarek Assi  1 , Joseph Kattan  1
Affiliations
Comparative Study

A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer

Elie El Rassy et al. Immunotherapy. 2018 Jun.

Abstract

Aim: To determine which of the approved immune checkpoint inhibitors is the optimal treatment in metastatic urothelial bladder cancer.

Methods & materials: Only the pivotal Phase III trials of second-line metastatic urothelial bladder cancer were included in this network meta-analysis.

Results: This NMA included three pooled trials (NCT00315237, NCT02256436 and NCT02302807) of 1125 participants. Pembrolizumab was the only treatment with positive effect on overall survival compared with the best supportive care. The treatment discontinuation rates due to adverse events of the pembrolizumab and atezolizumab did not differ from that of the best supportive care. C onclusion: Our results confirmed the superiority of pembrolizumab in the management of metastatic urothelial bladder cancer.

Keywords: PD-1 inhibitor; PDL-1 inhibitor; atezolizumab; pembrolizumab; urothelial bladder cancer.

PubMed Disclaimer

Publication types

MeSH terms

Associated data

LinkOut - more resources